We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-6 of 6

FDA moves forward with program for Medical Device Development Tools

  • Sidley Austin LLP
  • -
  • USA
  • -
  • September 8 2014

On August 15, 2014, FDA announced that it is soliciting proposals to participate in a pilot program for Medical Device Development Tools (MDDTs

New FDA MDDS draft guidance reduces regulatory hurdles for software developers, signals continued intent to “regulate” software via policy

  • Sidley Austin LLP
  • -
  • USA
  • -
  • June 25 2014

On June 20, 2014, FDA issued a draft guidance titled "Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications

FDA draft guidance on mobile apps signals increased regulatory oversight

  • Sidley Austin LLP
  • -
  • USA
  • -
  • July 27 2011

On July 20, 2011, the U.S. Food and Drug Administration (FDA) issued draft guidance identifying the mobile device applications“apps”the agency plans to regulate as medical devices

FDA shift on diagnostics lays groundwork for regulation of lab-developed tests global life sciences - U.S. FDA update

  • Sidley Austin LLP
  • -
  • USA
  • -
  • July 15 2011

On July 12, 2011, FDA’s Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) announced plans to down-classify and exempt from Section 510(k) premarket notification a range of in vitro diagnostic and radiology device types

New FDA draft guidance holds IVD manufacturers responsible for clinical use of ROUIUO products

  • Sidley Austin LLP
  • -
  • USA
  • -
  • June 16 2011

In a new proposed guidance, FDA has signaled its intention to shift responsibility for the use of certain medical devices from customers to manufacturers, based on an expansive and legally questionable presumption of “intent.”

U.S. Food and Drug Administration and European Medicines Agency enter into new good clinical practices collaboration

  • Sidley Austin LLP
  • -
  • European Union, USA
  • -
  • August 5 2009

On August 3, 2009, the U.S. Food and Drug Administration (FDA) announced a collaborative agreement with the European Medicines Agency (EMEA) for a Good Clinical Practices (GCP) Initiative